Telix Pharmaceuticals (NASDAQ:TLX) Receives Outperform Rating from Wedbush

Wedbush reiterated their outperform rating on shares of Telix Pharmaceuticals (NASDAQ:TLX) in a research report released on Monday morning,Benzinga reports. They currently have a $22.00 price objective on the stock.

A number of other analysts have also recently issued reports on TLX. Wall Street Zen upgraded shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, April 11th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Monday, April 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.12.

Telix Pharmaceuticals Trading Down 2.9%

NASDAQ TLX opened at $11.80 on Monday. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Telix Pharmaceuticals has a 12 month low of $6.28 and a 12 month high of $16.98. The company’s 50 day simple moving average is $10.27 and its 200 day simple moving average is $8.86.

Insiders Place Their Bets

In related news, CEO Christian Behrenbruch bought 33,435 shares of Telix Pharmaceuticals stock in a transaction that occurred on Wednesday, April 29th. The stock was purchased at an average cost of $14.87 per share, for a total transaction of $497,178.45. Following the acquisition, the chief executive officer owned 20,742,935 shares in the company, valued at $308,447,443.45. This trade represents a 0.16% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Hedge Funds Weigh In On Telix Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Bank of America Corp DE boosted its holdings in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after buying an additional 8,423 shares during the period. Lazard Asset Management LLC grew its stake in Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after buying an additional 39,400 shares during the last quarter. XY Capital Ltd bought a new position in Telix Pharmaceuticals in the 1st quarter worth $120,000. Private Advisor Group LLC raised its holdings in Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after acquiring an additional 128,070 shares during the period. Finally, Vident Advisory LLC acquired a new position in Telix Pharmaceuticals during the 4th quarter worth $204,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.